Home/Pipeline/APOE Gene Therapy

APOE Gene Therapy

Alzheimer's Disease (APOE4)

PreclinicalActive

Key Facts

Indication
Alzheimer's Disease (APOE4)
Phase
Preclinical
Status
Active
Company

About Voyager Therapeutics

Voyager Therapeutics is dedicated to developing transformative gene therapies for neurological disorders by leveraging human genetics and its proprietary TRACER™ capsid discovery platform. The company's strategy combines internal pipeline development with strategic platform collaborations to de-risk R&D and generate non-dilutive funding. Key achievements include the generation of novel, IV-administered capsids with enhanced brain tropism and a pipeline featuring multiple preclinical and IND-enabling programs for high-need conditions like Alzheimer's and ALS.

View full company profile

Other Alzheimer's Disease (APOE4) Drugs

DrugCompanyPhase
Alzheimer's Disease ProgramSelonterraPreclinical